February 12th 2025
A new patent was issued for Adial Pharmaceuticals’ identification of patients with specific genetic markers linked to substance use disorders and treatment with AD04.
Beyond Abstinence: Other Clinically Meaningful Endpoints for Patients With Substance Use Disorders
December 9th 2024While complete abstinence is a good goal, what other clinically meaningful endpoints are there for patients with substance use disorders? Learn more in this ACNP 2024 Annual Meeting session!
Read More